Navigation Links
FDA Reviews Side Effects From Prostate Cancer Therapy

Doctors urged to consider risks of hormone treatment, inform patients

MONDAY, May 3 (HealthDay News) -- A widely used class of prostate cancer drugs called gonadotropin-releasing hormone (GnRH) agonists increases the risk of diabetes, heart attack, stroke and sudden death in men, a U.S. Food and Drug Administration review has found.

Based on initial findings from a preliminary and ongoing analysis of several studies, the FDA says doctors should be aware of the potential risks of GnRH agonists, and carefully consider the benefits and risks of these drugs when deciding on treatment for prostate cancer patients.

The agency also recommended that:

  • Patients taking GnRH agonists should be checked regularly for signs of the development of diabetes and cardiovascular disease.
  • Management of cardiovascular risk factors -- including smoking, as well as increases in blood pressure, cholesterol, blood sugar and weight -- should be stressed.
  • Those taking GnRH agonists should not stop the therapy unless instructed by their health-care provider.

Drugs in the GnRH agonist class include Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic products. These drugs suppress production of testosterone, a hormone involved in the growth of prostate cancer.

"While our review of these prostate cancer treatments is ongoing and there are some limitations to the data, FDA believes it is important to tell patients and health-care professionals that there may be an increased risk of serious side effects," Dr. Robert Justice, director of the drug oncology products division at FDA's Center for Drug Evaluation and Research, said in a news release.

Some GnRH agonists are also used to treat conditions in women and children.

More information

The U.S. National Cancer Institute has more about prostate cancer treatments.

-- Robert Preidt

SOURCE: U.S. Food and Drug Administration, news release, May 3, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. CBDM.T, The Market and Business Intelligence Company Reviews The Dry Eye Disease Treatment Market
2. Hollywood Eco-Celebrity Rachelle Carson-Begley Gives Skincare Company Bella V Rave Reviews
3. WebLOQ Selected By MARSI to Streamline Medical Audit Reviews From Dispersed Healthcare Community
4. New Book Reviews Core Competencies for Pharmacy Leaders
5. HCA Previews Fourth Quarter and Year-End 2009 Results
6. Hearing Aid Reviews Go Public on Advice on Hearing Aids
7. Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill
8. Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV
9. Finding cancer cold spots can help minimize radiotherapy side-effects
10. Adverse drug effects in epileptic patients not correlated with number of prescribed medications
11. Most women facing gynecologic surgery dont worry about its effects on sex
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... The recently published 32nd Annual Report of ... that in 2014, someone called a poison center about every 11 seconds. America’s ... human exposure cases. , The American Association of Poison Control Centers (AAPCC) maintains ...
(Date:11/30/2015)... ... November 30, 2015 , ... The Foundation for Breast ... and prevention—is joining forces with the award-winning creator and writer of Downton Abbey ... 7, 2015 at the Union League of Philadelphia. , The benefit, titled ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as supporting ... so for a child’s exposure limits. , The original Nov 2015 CR story ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is concerned about ... baby had high blood pressure due to loud noises," she said, "so I decided ... noise pollution as well as radio waves and microwaves." , The baby BABY MUFF ...
(Date:11/30/2015)... CHICAGO (PRWEB) , ... November ... ... introduced two new additions to its industry-leading suite of automated breast density ... of North America (RSNA) meeting, November 29-December 4, 2015 (South Hall booth ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology: